Teva Pharmaceutical Industries Limited (NYSE:TEVA) has been given a $38.00 price objective by Royal Bank Of Canada in a note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 21.01% from the company’s previous close.

Several other analysts also recently weighed in on the company. Cantor Fitzgerald began coverage on Teva Pharmaceutical Industries Limited in a research note on Thursday. They set a “neutral” rating and a $31.00 target price on the stock. Mizuho raised Teva Pharmaceutical Industries Limited from a “neutral” rating to a “buy” rating and lifted their target price for the company from $25.00 to $30.00 in a research note on Thursday. BidaskClub raised Teva Pharmaceutical Industries Limited from a “strong sell” rating to a “sell” rating in a research note on Tuesday, June 13th. Vetr downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating and set a $31.05 target price on the stock. in a research note on Monday, June 12th. Finally, ValuEngine downgraded Teva Pharmaceutical Industries Limited from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. One analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $43.56.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded up 1.3428% during midday trading on Friday, hitting $31.3352. The stock had a trading volume of 3,662,548 shares. The firm has a market cap of $31.84 billion, a PE ratio of 401.7333 and a beta of 0.49. The stock has a 50-day moving average price of $30.19 and a 200 day moving average price of $33.22. Teva Pharmaceutical Industries Limited has a one year low of $27.60 and a one year high of $56.44.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, May 11th. The company reported $1.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.06. The business had revenue of $5.63 billion for the quarter, compared to the consensus estimate of $5.69 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.38% and a net margin of 1.49%. The business’s revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business posted $1.20 EPS. On average, analysts predict that Teva Pharmaceutical Industries Limited will post $4.79 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 22nd. Investors of record on Monday, June 5th will be given a dividend of $0.34 per share. The ex-dividend date is Thursday, June 1st. This represents a $1.36 annualized dividend and a dividend yield of 4.33%. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently 5,802.90%.

ILLEGAL ACTIVITY WARNING: “Royal Bank Of Canada Analysts Give Teva Pharmaceutical Industries Limited (TEVA) a $38.00 Price Target” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/17/royal-bank-of-canada-reaffirms-buy-rating-for-teva-pharmaceutical-industries-limited-teva.html.

Several institutional investors have recently bought and sold shares of TEVA. Franklin Resources Inc. boosted its position in Teva Pharmaceutical Industries Limited by 20.9% in the fourth quarter. Franklin Resources Inc. now owns 56,635,303 shares of the company’s stock valued at $2,052,926,000 after buying an additional 9,775,505 shares in the last quarter. Highfields Capital Management LP boosted its position in Teva Pharmaceutical Industries Limited by 106.2% in the fourth quarter. Highfields Capital Management LP now owns 16,867,447 shares of the company’s stock valued at $611,445,000 after buying an additional 8,686,905 shares in the last quarter. Paulson & CO. Inc. acquired a new position in Teva Pharmaceutical Industries Limited during the fourth quarter valued at $577,310,000. Norges Bank acquired a new position in Teva Pharmaceutical Industries Limited during the fourth quarter valued at $495,909,000. Finally, Alliancebernstein L.P. boosted its position in Teva Pharmaceutical Industries Limited by 7.3% in the first quarter. Alliancebernstein L.P. now owns 8,617,143 shares of the company’s stock valued at $276,524,000 after buying an additional 587,286 shares in the last quarter. 56.26% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.